Review and commentary on the role of radiation therapy in the adjuvant management of pancreatic cancer

Anand P. Shah, Jonathan B. Strauss, Ross A. Abrams

Research output: Contribution to journalReview articlepeer-review

10 Scopus citations

Abstract

Currently, pancreatic cancer is fatal in over 90% of cases. Complete resection (if possible) is required for cure but the optimal adjuvant therapy is controversial. Given that pancreatic cancer frequently recurs both locoregionally and distantly, oncologic principles support the role of both adjuvant chemotherapy and radiotherapy. The historic trials evaluating chemoradiotherapy are too limited to provide clear guidance, but when viewed together with single institution data they suggest that chemoradiotherapy is beneficial. New data strongly support the use of adjuvant gemcitabine chemotherapy, but the benefit of the addition of radiation is still under investigation and no consensus exists on a standard of care. Clearly, no combination of currently available agents is sufficient to provide acceptable cure rates in pancreatic cancer and novel therapies must be found.

Original languageEnglish (US)
Pages (from-to)101-106
Number of pages6
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume33
Issue number1
DOIs
StatePublished - Feb 1 2010

Keywords

  • Chemotherapy
  • ESPAC
  • GITSG
  • Pancreatic cancer
  • Radiation

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Review and commentary on the role of radiation therapy in the adjuvant management of pancreatic cancer'. Together they form a unique fingerprint.

Cite this